BioMarin Pharmaceutical and several officers and executives were hit with a securities class action Friday in California Northern District Court in connection with statements related to a drug candidate for the treatment of phenylketonuria. The lawsuit, filed by Pomerantz LLP, contends that the defendants misled investors regarding adverse safety findings. Counsel have not yet appeared for the defendants. The case is 5:21-cv-08254, Berlinger v. BioMarin Pharmaceutical Inc. et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.

Read the complaint here: